Q-omics provides the consensus-scored FAM245A profile across patient tissues and cancer cell-line models. FAM245A expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FAM245A is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, FAM245A RNA expression shows 7,167 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight CESC, KIRC, and PDAC as cancer lineages where FAM245A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM245A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM245A survival associations across molecular data types. FAM245A RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM245A RNA expression–survival associations across cancer types. High FAM245A expression shows unfavorable associations in CESC, OV, LUAD, BRCA, ESCA and UCEC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for FAM245A RNA expression.
This table summarizes FAM245A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM245A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM245A shows lower tumor expression in KIRC, KICH, KIRP, LIHC and LUAD and higher tumor expression in COAD. The KIRC box plot shows higher FAM245A RNA expression in normal versus tumor tissue (log2 FC = −2.930, t-test p < 0.001).
This table shows molecular features associated with FAM245A in patient tissues and cancer cell lines. In patient samples, FAM245A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
